bb2121 is a chimeric antigen receptor (CAR) T-cell product targeting the B-cell maturation antigen (BCMA), which is universally expressed on plasma cells (myemola cells). At the European Hematology Association (EHA) 2017 meeting, Yi Lin, MD, PhD from the Mayo Clinic, Rochester, MN, presented the latest data from a multicenter study in patients with relapsed/refractory multiple myeloma.